1058137-23-7

Basic information

• Product Name: E-3810
• Synonyms: E-3810;6-[[7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide;E-3810(Lucitanib);Lucitanib;6-[[7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide E-3810(Lucitanib);6-((7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-N-methyl-1-naphthamide;AL3810;6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide
• CAS NO: 1058137-23-7
• Molecular Formula: C26H25N3O4
• Molecular Weight: 443.4944
• Mol File: 1058137-23-7.mol

Chemical Properties

• Boiling Point: 696.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.285±0.06 g/cm3(Predicted)
• Solubility: Soluble in DMSO
• PKA: 14.65±0.46(Predicted)
• CAS DataBase Reference: E-3810(CAS DataBase Reference)
• NIST Chemistry Reference: E-3810(1058137-23-7)
• EPA Substance Registry System: E-3810(1058137-23-7)

Safety Data

• Hazardous Substances Data: 1058137-23-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
E-3810 is used as an active pharmaceutical ingredient for its potential therapeutic effects. The compound's unique structure allows it to interact with specific biological targets, making it a promising candidate for the development of new drugs to treat various diseases and conditions.
Used in Chemical Synthesis:
In the chemical industry, E-3810 can be used as a key intermediate or building block in the synthesis of more complex molecules. Its versatile chemical structure enables it to be modified and functionalized, leading to the creation of new compounds with specific properties and applications.
Used in Research and Development:
E-3810 serves as an important research tool in the field of medicinal chemistry and drug discovery. Scientists and researchers can use E-3810 to study its interactions with biological targets, evaluate its pharmacological properties, and investigate its potential as a therapeutic agent.
Used in Material Science:
The unique chemical structure of E-3810 may also find applications in the field of material science. It could be used to develop new materials with specific properties, such as improved stability, enhanced reactivity, or tailored physical characteristics, depending on the desired application.

Upstream product

• 286371-49-1 7-(benzyloxy)-4-chloro-6-methoxyquinoline 
• 847802-91-9 6-hydroxy-N-methyl-1-naphthalenecarboxamide 
• 2437-17-4 6-hydroxy-1-naphthoic acid 
• 1058137-70-4 6-(7-(benzyloxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide 
• 1058137-21-5 benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate 

Relevant articles and documents

Crystal form of lucitanib

The invention relates to a crystal form of lucitanib. The invention belongs to the technical field of medicine crystal forms, and particularly relates to a lucitanib dihydrate, a lucitanib crystal form II and a lucitanib dihydrochloride dihydrate, and preparation methods and applications thereof.

PROCESS FOR PREPARING THE ANTI-TUMOR AGENT 6-(7-((1-AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND ITS CRYSTALLINE

The present invention relates a new process to synthesize 6-(7-((l-aminocyclo-propyl)- methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- l -naphthamide (AL3810) by deprotection of substituted benzyl 1 -((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)- methyl)cyc-lopropylcarbamate (Formula I) under a diluted or weak acidic condition. A stable crystalline form of 6-(7-((l-aminocyclo-propyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N- methyl- 1 -naphthamide has also been prepared.

A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF

A process for the preparation in high yields and purity of the compound 6-(7-((l-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide of formula (I) and of the pharmaceutically acceptable salts thereof is described. The process has various advantages over those previously described, in particular it avoids the use of acyl azide intermediates and their Curtius rearrangement. Novel intermediates useful for the preparation of compound (I) are also described.

SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS

The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans